TransMedics Group (NASDAQ:TMDX) Now Covered by Evercore ISI

Evercore ISI assumed coverage on shares of TransMedics Group (NASDAQ:TMDX) in a research report released on Tuesday, MarketBeat.com reports. The brokerage issued an outperform rating and a $155.00 price target on the stock.

Several other analysts have also recently commented on TMDX. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Monday, August 25th. Piper Sandler reiterated an “overweight” rating and set a $145.00 price target (up from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Stifel Nicolaus assumed coverage on TransMedics Group in a research note on Thursday, September 4th. They set a “hold” rating and a $115.00 price target on the stock. Morgan Stanley upped their price target on TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st. Finally, Canaccord Genuity Group lifted their price objective on TransMedics Group from $129.00 to $142.00 and gave the stock a “buy” rating in a report on Tuesday, July 15th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $125.40.

TransMedics Group Stock Up 4.3%

TMDX opened at $119.15 on Tuesday. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17. TransMedics Group has a 12 month low of $55.00 and a 12 month high of $169.29. The stock has a market capitalization of $4.06 billion, a P/E ratio of 61.74 and a beta of 2.18. The business has a 50 day simple moving average of $115.82 and a 200-day simple moving average of $106.11.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The firm had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. During the same quarter in the prior year, the company posted $0.35 earnings per share. TransMedics Group’s quarterly revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that TransMedics Group will post 1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Cetera Investment Advisers lifted its stake in TransMedics Group by 8.3% in the 4th quarter. Cetera Investment Advisers now owns 8,260 shares of the company’s stock valued at $515,000 after buying an additional 634 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of TransMedics Group by 6.2% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,657 shares of the company’s stock valued at $1,163,000 after acquiring an additional 1,096 shares in the last quarter. Nomura Holdings Inc. purchased a new stake in shares of TransMedics Group in the fourth quarter valued at $459,000. ProShare Advisors LLC boosted its stake in shares of TransMedics Group by 62.5% during the fourth quarter. ProShare Advisors LLC now owns 10,064 shares of the company’s stock valued at $627,000 after acquiring an additional 3,870 shares during the last quarter. Finally, Two Sigma Investments LP purchased a new stake in TransMedics Group during the 4th quarter worth about $781,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.